Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Oct 30;26(4):672–682. doi: 10.1016/j.bbmt.2019.10.016

Table 2:

Adjusted Hazard Ratios for Time to Mortality

Unadjusted Adjusted
Measure HR 95% Cl p-value HR 95% Cl p-value
Inhibitory KIR 2.7 1.5, 4.6 0.0006 2.1 1.2, 3.6 0.0059
Activating KIR 1.2 0.7, 2.0 0.4126 1.3 0.7, 2.4 0.3437
Missing KIR 3.2 1.7, 6.0 0.0004 2.7 1.5, 5.1 0.0015
CD34 Dose 1.3 1.0, 1.6 0.0319
Age 0.9 0.9,1.0 0.0003
Sex F vs M 1.1 0.5, 2.3 0.7909
Treatment Intensity M vs RIT 1.4 0.7, 3.0 0.3214
ATG Y vs N 0.8 0.2, 3.0 0.7373
Donor Haplotype A vs B 1.6 0.7, 3.8 0.2928
Myeloid Disease Y vs N 1.5 0.7, 3.2 0.2938
Disease State CR1 vs Other 1.1 0.5, 2.4 0.8853